- Messages
- 88
Cincinnati Children's Hospital just patented a system for transcription factor modification to treat autoimmune diseases. Here is a youtube video about the problem:
And here is the patent that (maybe?) helps treat the issue described in the above video:
Abstract: "Disclosed herein are methods of treatment of various disease states in which an individual in need thereof if administered one or more therapeutic agents capable of modulating one or more transcription factors. Also disclosed are methods by which an individual may be treated for one or more disease states, in which loci in which transcription factors bind are detected."
http://appft1.uspto.gov/netacgi/nph...srchnum.html&r=1&f=G&l=50&s1=20180016314.PGNR.
For some reason I can't add a period on the end of this link. If you add a period, then the link works.
Here is a quote from reddit about the patent:
"They basically patented the ability to use specific drugs to target specific transcription factors and to treat dozens of different diseases. They found associations with the levels of various different transcription factors and the diseases and identified ways that modifications to them can affect the genes that are implicated in the disease. Whether of not that actually affects the disease process, or is even a viable or safe technique in living cells, let alone patients, is still up for question but it provides a new avenue for exploration.
The video I linked to above identifies one such transcription factor that they found was not native to humans and through association studies they were able to link it to Epstein Barr Virus. They haven't actually published that paper yet so I don't know how they managed to prove that association or to understand exactly how key the EBNA2 gene is to the pathogenesis of the autoimmune diseases they identified. EBNA2 has not really been studied by anyone else before so this is totally new ground.
The entire idea of transcription factor modification has been around for a while but nobody has identified any real targets until now."
There is almost no chance that EBV effects these autoimmune diseases but not ME/CFS in a similar way. Maybe even more-so, due to the strong relationship between getting mono and ME/CFS.
Can someone show this to Dr Davis et all?
And here is the patent that (maybe?) helps treat the issue described in the above video:
Abstract: "Disclosed herein are methods of treatment of various disease states in which an individual in need thereof if administered one or more therapeutic agents capable of modulating one or more transcription factors. Also disclosed are methods by which an individual may be treated for one or more disease states, in which loci in which transcription factors bind are detected."
http://appft1.uspto.gov/netacgi/nph...srchnum.html&r=1&f=G&l=50&s1=20180016314.PGNR.
For some reason I can't add a period on the end of this link. If you add a period, then the link works.
Here is a quote from reddit about the patent:
"They basically patented the ability to use specific drugs to target specific transcription factors and to treat dozens of different diseases. They found associations with the levels of various different transcription factors and the diseases and identified ways that modifications to them can affect the genes that are implicated in the disease. Whether of not that actually affects the disease process, or is even a viable or safe technique in living cells, let alone patients, is still up for question but it provides a new avenue for exploration.
The video I linked to above identifies one such transcription factor that they found was not native to humans and through association studies they were able to link it to Epstein Barr Virus. They haven't actually published that paper yet so I don't know how they managed to prove that association or to understand exactly how key the EBNA2 gene is to the pathogenesis of the autoimmune diseases they identified. EBNA2 has not really been studied by anyone else before so this is totally new ground.
The entire idea of transcription factor modification has been around for a while but nobody has identified any real targets until now."
There is almost no chance that EBV effects these autoimmune diseases but not ME/CFS in a similar way. Maybe even more-so, due to the strong relationship between getting mono and ME/CFS.
Can someone show this to Dr Davis et all?
Last edited: